Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
43.92
+1.41 (3.32%)
At close: Sep 26, 2025, 4:00 PM EDT
43.96
+0.04 (0.09%)
After-hours: Sep 26, 2025, 7:18 PM EDT
Revolution Medicines Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
534
Market Cap
8.21B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | 11.58M | -23.80M | -67.27% |
Dec 31, 2022 | 35.38M | 5.99M | 20.38% |
Dec 31, 2021 | 29.39M | -13.59M | -31.62% |
Dec 31, 2020 | 42.98M | -7.06M | -14.10% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
RVMD News
- 16 days ago - Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug - Benzinga
- 16 days ago - Revolution Medicines: Shares Soar On Pancreatic Cancer Study Win - I'm Sold - Seeking Alpha
- 16 days ago - Revolution Medicines, Inc. (RVMD) Discussion On Metastatic Pancreatic Cancer Update Call (Transcript) - Seeking Alpha
- 17 days ago - Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma - GlobeNewsWire
- 7 weeks ago - Revolution Medicines, Inc. (RVMD) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress - GlobeNewsWire
- 2 months ago - Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025 - GlobeNewsWire
- 2 months ago - Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor - GlobeNewsWire